Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Large-Scale Exercise of the 70th Stock Acquisition Rights (with an Exercise Price Adjustment Clause) Issued through a Third-Party Allotment

On 6 November 2026, 56,000 of the 70th Stock Acquisition Rights were exercised and 5,600,000 new shares were delivered. As a result, the balance of unexercised rights decreased from 328,460 to 272,460.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
5600000
shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Large-scale exercise of the 70th Stock Acquisition Rights (with an Exercise Price Adjustment Clause) issued through a third-party allotment

発行・処分する株式数5,600,000Shares

5,600,000 new shares

Intended allottee
EVO FUND (allottee of the previously issued stock acquisition rights)
Terms of the stock acquisition rights
Exercise price
¥73. The floor under the exercise price adjustment clause is Not disclosed
Number of Stock Acquisition Rights
Total issued: 480,000 rights; balance of unexercised rights at the time of the previous disclosure: 328,460; balance of unexercised rights as of 6 November 2026: 272,460
Payment date
2 September 2026
Procedures under the Corporate Code of Conduct
The purchase agreement stipulates that the prohibition on exercises exceeding the applicable limit does not apply when the exercise price is at or above the closing price on 17 August 2026, the date of the issuance resolution
Most recent equity financing
Timing 2 September 2026 / Type Issuance through a third-party allotment of the 70th and 71st Stock Acquisition Rights (with an Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalLarge-scale exercise of the 70th Stock Acquisition Rights (with an Exercise Price Adjustment Clause) issued through a third-party allotment
Number of shares to be issued or disposed of5,600,000 new shares
Payment date2 September 2026
Intended allotteeEVO FUND (allottee of the previously issued stock acquisition rights)
Exercise price¥73. The floor under the exercise price adjustment clause is Not disclosed
Number of Stock Acquisition RightsTotal issued: 480,000 rights; balance of unexercised rights at the time of the previous disclosure: 328,460; balance of unexercised rights as of 6 November 2026: 272,460
Procedures under the Corporate Code of ConductThe purchase agreement stipulates that the prohibition on exercises exceeding the applicable limit does not apply when the exercise price is at or above the closing price on 17 August 2026, the date of the issuance resolution
Most recent equity financingTiming 2 September 2026 / Type Issuance through a third-party allotment of the 70th and 71st Stock Acquisition Rights (with an Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that the exercise exceeded 10% of the number of listed shares because, under the purchase agreement for these Stock Acquisition Rights, the prohibition on exercises exceeding the applicable limit does not apply when the exercise price is at or above the closing price on 17 August 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the 70th Stock Acquisition Rights (with an Exercise Price Adjustment Clause) Issued through a Third-Party Allotment | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori